Short interest for INVO Bioscience gives investors a sense of the degree to which investors are betting on the decline of INVO Bioscience's stock. Short interest data is updated every two weeks.

INVO Bioscience Stock (NASDAQ:INVO), Short Interest Report

INVO Bioscience

INVO Bioscience Inc operates a healthcare services fertility company. Assisted Reproductive Technology (ART) marketplace by making fertility care more accessible and inclusive to people. Its commercial strategy is focused on operating fertility-focused clinics, which includes the opening of dedicated INVO Centers offering the INVOcell and IVC procedure (with three centers in North America now operational) and the acquisition of US-based, profitable in vitro fertilization (IVF) clinics. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors.

alibaba_logo

News

Intraday Update

Markets

Movers

AGYS

AKYA

AUGX

BABA

BETR

BIOL

BYND

CLOV

CTNT

DCTH

DWSN

EAST

FENC

FFIE

FOSL

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HROW

INVO

JAMF

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MBIN

NOTV

NOVA

ONON

PLUG

PSFE

RENT

SCPX

SHIM

SMRT

Sony Group Corporation American Depositary Shares

SONY

SPCE

SPWR

STNE

SYRA

TLRY

UXIN

VUZI

WOOF

WULF

Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

xr:d:DAFinCU7viM:2,j:4467771911,t:23051112

Pre-Market Outlook

Trading Ideas

APDN

WRNT

Why Alcon Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Earnings

AGBA

AILE

ALRN

APOG

BENF

BPTH

EDBL

NRXP

OCUL

SINT

SMSI

SMXT

SPCB

THCH

TIRX

TLSA

TOON

VTNR

WINT

WISA

XPON

Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

INVO Bioscience Inc

InvoCare Ltd

Macro Economic Events

WIIM

Economics

Oil is trading higher following a larger-than-expected draw in US crude inventories.

Over the past 24 hours, Lido Staked Ether's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">STETH</a>) price has risen 3.8% to $2,991.94. This is contrary to its negative trend over the past week where it has experienced a 1.0% loss, moving from $3,010.63 to its current price. As it stands right now, the coin's all-time high is $4,829.57. 
The chart below compares the price movement and volatility for Lido Staked Ether over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715799821_0.png" alt="price_chart" />
The trading volume for the coin has increased 2.0% over the past week while the overall circulating supply of the coin has increased 0.08% to over 9.37 million. The current market cap ranking for STETH is #8 at $27.97 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715799821_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$STETH

Lido Staked Ether Up More Than 3% In 24 hours

BMO Capital&nbsp;analyst Brian Pitz reiterated&nbsp;Google&nbsp;parent&nbsp;Alphabet&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with an Outperform and a&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/GOOGL/analyst-ratings" rel="noreferrer noopener">$215&nbsp;price target</a>.
The analyst said&nbsp;Google I/O contextualized&nbsp;how Alphabet will integrate and monetize over twenty years of AI initiatives and pursue the first&nbsp;big&nbsp;search&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/05/38826439/at-google-io-2024-sundar-pichai-and-team-announces-new-gemini-models-project-astra-ai-fraud-protecti" rel="noreferrer noopener">transformation in as many years with Project Astra.</a>&nbsp;
Pitz noted, specifically,&nbsp;the monetization of AI Overview improving ROAS, the cost to serve declining 80%, and Gemini integrating at the OS level across smartphones.
Bears likely argued that recent OpenAI multimodal Agent demos are more advanced, but he argued that GOOGL leverages significant scale advantages and ecosystem integration over time.
JMP Securities&nbsp;analyst Andrew Boone reaffirmed Alphabet with a Market Outperform and a $200&nbsp;price target.
With Google&#8217;s AI models able to better understand queries, respond to complex searches, and curate information for users, Boone noted Google can unlock more queries with AI-powered search. The analyst flagged that AI is significantly improving Google&#8217;s entire product suite as each of its six products with over 2 billion MAU has integrated AI features.
While he acknowledged the risk of search changing as it goes from a web crawler-based service to an AI model-powered service, which could increase competition and disrupt its distribution with partners, Google&#8217;s growing data corpus, compute infrastructure, and deep integrations with over 5 million advertisers can sustain its share of monetizable searches. 
The price target reflects Google&#8217;s vast TAM, its scale across search, video, and the cloud, and high profitability.
BofA Securities&nbsp;analyst Justin Post maintained a Buy rating on Alphabet with a price target of $200.
The Google I/O keynote was packed with announcements featuring Gemini integration across Google&#8217;s ecosystem, including Search, Workspace, Android, and Assistant, Post said. The event also included the launch of various improved LLMs and 6th-generation TPUs. 
The analyst noted that I/O supported his thesis that Google has industry-leading AI/ML capabilities, and the pace of AI innovation has accelerated. As per the analyst, Google is a net AI beneficiary, and growing generative AI (GenAI) integrations should likely drive higher usage and incremental spending across Search, Cloud, and Workspace. 
KeyBanc&nbsp;analyst Justin Patterson reiterated an Overweight rating on Alphabet with a price target of $200.
Patterson came away from Google I/O 2024 impressed by the speed at which Google has made AI accessible for consumers, enterprises, and developers (Gemini is now part of all of Google&#8217;s two billion+ user products). AI agent Astra stole the show on how GenAI is revolutionizing assistants, he said. 
Likewise, search generative experience (SGE) is now rolling out into core search as AI Overviews, which the analyst noted suggests both the user experience and cost curves are under control. 
Rosenblatt&nbsp;analyst Barton Crockett maintained a Buy rating on Alphabet with a price target of $182.
The analyst noted that Google&#8217;s two-hour I/O developer conference keynote address overviewed the widespread propagation of AI features across Google products and services. 
But, on the feature that OpenAI made the centerpiece of its 26-minute AI update presentation the day prior, which involved live audio chat and an AI model with great facility in detecting and conveying emotional tone, Alphabet&#8217;s presentation was limited, suggesting a lead for OpenAI right now in that capability. 
To his mind, this supports the notion that Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) could turn to OpenAi to help upgrade Siri and related AI features.
Stifel&nbsp;analyst maintained Alphabet with a Buy and a $196&nbsp;price target.
Price Action: GOOGL shares traded higher by 1.03% at $172.10 at the last check Wednesday.
Photo via Shutterstock

Analyst Color

Equities

Price Target

Reiteration

Analyst Ratings

Tech

AAPL

GOOGL

Google Advances AI Integration, While Apple May Partner with OpenAI to Enhance Siri, Analysts Say

Analysts' ratings for IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $10.62, a high estimate of $15.00, and a low estimate of $6.00. A 21.33% drop is evident in the current average compared to the previous average price target of $13.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1715799781_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive IHS Holding. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colby Synesael</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Maurice Patrick</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$6.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Gregory Williams</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.50</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to IHS Holding. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of IHS Holding compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of IHS Holding's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of IHS Holding's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IHS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IHS Holding analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into IHS Holding's Background</h2>
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, most of who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
<h3>Financial Milestones: IHS Holding's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: IHS Holding's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -3.11%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Communication Services sector.
Net Margin: IHS Holding's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -93.98%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): IHS Holding's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -262.18%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -8.79%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: IHS Holding's debt-to-equity ratio surpasses industry norms, standing at 37.44. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For IHS Holding

During the last three months, 9 analysts shared their evaluations of Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $40.11, a high estimate of $55.00, and a low estimate of $21.00. This current average reflects an increase of 7.25% from the previous average price target of $37.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1715799757_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Regenxbio. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Annabel Samimy</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$36.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$39.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Andreas Argyrides</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Dane Leone</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$45.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Regenxbio. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regenxbio compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Regenxbio's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Regenxbio's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RGNX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Regenxbio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Regenxbio's Background</h2>
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
<h3>Regenxbio: Financial Performance Dissected</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Negative Revenue Trend: Examining Regenxbio's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -18.37% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Regenxbio's net margin excels beyond industry benchmarks, reaching -405.39%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Regenxbio's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -18.03%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Regenxbio's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.53%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.22, Regenxbio faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RGNX

Evaluating Regenxbio: Insights From 9 Financial Analysts

Mizuho Securities raised the price target for&nbsp;Boston Scientific Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), saying the cardiology segment is poised to deliver double-digit growth.
Citing the virtual NDR group meeting, Mizuho Securities Managing Director Anthony Petrone said high-level feedback suggests that the cardiology segment is poised to maintain a &#8220;healthy&#8221; double-digit top-line growth profile for the foreseeable future supported by rapid Farapulse adoption, Watchman FLX upside from combo pulsed field ablation concomitant surgery with left atrial appendage closure (PFA and LAAC) surgery, and core CRM renaissance supported by Emblem S-ICD adoption.
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38411015/boston-scientific-lifts-2024-profit-forecast-on-strong-growth-from-cardiovascular-devices-stock-soa" rel="noreferrer noopener">Boston Scientific Lifts 2024 Profit Forecast On Strong Growth From Cardiovascular Devices, Stock Soars</a>.
Mizuho wrote, &#8220;Feedback supports our view that U.S. Farapulse contribution can approach our $400 million bull case scenario this year while combo PFA + LAAC surgery can drive Watchman FLX growth back over +20% heading into next year.&#8221;
With a Buy rating, Mizuho increased the&nbsp;<a href="https://www.benzinga.com/quote/BSX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $85 to $90</a>, and cited that the scenarios from PFA and LAAC combo surgery volumes support a higher $115 bull case price target.
The analyst said the Farapulse launch in the U.S. mirrored its European rollout. Faster ablation times increased capacity by about 36%, leading to more scheduled cases.&nbsp;
The company anticipates that results from their persistent atrial fibrillation (AF) trials will boost awareness and treatment, further expanding the PFA market.
Boston Scientific anticipates substantial growth for its blockbuster product, already generating over $1 billion, with a near-term growth projection of +20% due to deeper market penetration. 
The Option trial is evaluating the Watchman device as an alternative to anticoagulation following ablation procedures. Data are expected in late 2024 or early 2025, leading to label expansion and increased use. 
The Champion trial results, expected in the first half of 2026, could further extend the product&#8217;s use to AF patients before ablation. Concerns about competition from new Factor 11 inhibitor anticoagulants seem overstated due to their uncertain efficacy, high cost and need for regular injections.
Mizuho noted, &#8220;All in, the momentum in Watchman is likely to continue for years driven by increased penetration through label expansions combined with updated guidelines and reimbursement tailwinds.&#8221;
BSX Price Action:&nbsp;Boston Scientific Corporation shares are up 0.94% at $74.18&nbsp;at last check&nbsp;Wednesday.
Photo: Shutterstock

Large Cap

Health Care

General

Boston Scientific's Upside With Cardiology Devices Drives Momentum

Bitcoin Cash's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bch/usd">BCH</a>) price has increased 4.95% over the past 24 hours to $452.86, which is in the opposite direction of its trend over the past week, where it has experienced a 3.0% loss, moving from $460.13 to its current price. As it stands right now, the coin's all-time high is $3,785.82. 
The chart below compares the price movement and volatility for Bitcoin Cash over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715799752_0.png" alt="price_chart" />
The trading volume for the coin has decreased 25.0% over the past week, while the overall circulating supply of the coin has increased 0.2% to over 19.71 million. This puts its current circulating supply at an estimated 93.84% of its max supply, which is 21.00 million. The current market cap ranking for BCH is #17 at $8.86 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715799752_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$BCH

Bitcoin Cash Up More Than 4% In 24 hours

Throughout the last three months, 5 analysts have evaluated Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $9.92, a high estimate of $17.00, and a low estimate of $4.60. This current average has increased by 48.06% from the previous average price target of $6.70. 
<img src="https://www.benzinga.com/files/images/story/2024/1715799748_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Allogene Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$4.60</td>
<td>$4.40</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Allogene Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Allogene Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Allogene Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Allogene Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALLO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Allogene Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Allogene Therapeutics Better</h2>
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
<h3>Unraveling the Financial Story of Allogene Therapeutics</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Challenges: Allogene Therapeutics's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -26.67%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Allogene Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -295454.55%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Allogene Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -13.35%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -10.58%, the company showcases effective utilization of assets.
Debt Management: Allogene Therapeutics's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLO

Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views

Chainlink's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>) price has increased 4.97% over the past 24 hours to $13.73, which is in the opposite direction of its trend over the past week, where it has experienced a 2.0% loss, moving from $14.01 to its current price. As it stands right now, the coin's all-time high is $52.70. 
The chart below compares the price movement and volatility for Chainlink over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715799743_0.png" alt="price_chart" />
The trading volume for the coin has risen 9.0% over the past week diverging from the circulating supply of the coin, which has decreased 0.96%. This brings the circulating supply to 587.10 million, which makes up an estimated 58.71% of its max supply of 1.00 billion. According to our data, the current market cap ranking for LINK is #19 at $8.02 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715799743_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$LINK

Chainlink Up More Than 4% In 24 hours

Ratings for Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Boot Barn Holdings, presenting an average target of $113.0, a high estimate of $127.00, and a low estimate of $90.00. This upward trend is apparent, with the current average reflecting a 17.71% increase from the previous average price target of $96.00.
<img src="https://www.benzinga.com/files/images/story/2024/1715799736_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Boot Barn Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeremy Hamblin</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Janine Stichter</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$125.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>John Lawrence</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Max Rakhlenko</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Janine Stichter</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Boot Barn Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Boot Barn Holdings compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Boot Barn Holdings's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Boot Barn Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BOOT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Boot Barn Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind Boot Barn Holdings</h2>
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
<h3>Understanding the Numbers: Boot Barn Holdings's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Boot Barn Holdings showcased positive performance, achieving a revenue growth rate of 1.14% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.69%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Boot Barn Holdings's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 6.31%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Boot Barn Holdings's ROA stands out, surpassing industry averages. With an impressive ROA of 3.42%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Boot Barn Holdings's debt-to-equity ratio is below the industry average at 0.48, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BOOT

The Latest Analyst Ratings For Boot Barn Holdings

Cardano's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) price has increased 3.77% over the past 24 hours to $0.45, which is in the opposite direction of its trend over the past week, where it has experienced a 4.0% loss, moving from $0.46 to its current price. As it stands right now, the coin's all-time high is $3.09. 
The chart below compares the price movement and volatility for Cardano over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715799674_0.png" alt="price_chart" />
The trading volume for the coin has decreased 40.0% over the past week, while the overall circulating supply of the coin has decreased 0.07% to over 35.35 billion. This puts its current circulating supply at an estimated 78.55% of its max supply, which is 45.00 billion. The current market cap ranking for ADA is #11 at $15.79 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715799674_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$ADA

Cardano Rises More Than 3% In 24 hours

AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated AdaptHealth and provided 12-month price targets. The average target is $13.0, accompanied by a high estimate of $13.00 and a low estimate of $13.00. Surpassing the previous average price target of $11.00, the current average has increased by 18.18%.
<img src="https://www.benzinga.com/files/images/story/2024/1715799667_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of AdaptHealth among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$13.00</td>
<td>-</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AdaptHealth. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of AdaptHealth compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of AdaptHealth's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AHCO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AdaptHealth analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About AdaptHealth</h2>
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.
<h3>Understanding the Numbers: AdaptHealth's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: AdaptHealth displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 6.89%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: AdaptHealth's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -0.36%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.15%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.05%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.6, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AHCO

Breaking Down AdaptHealth: 4 Analysts Share Their Views

Republic Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) has outperformed the market over the past 15 years by 2.9% on an annualized basis producing an average annual return of 15.49%. Currently, Republic Servs has a market capitalization of $58.83 billion. 
Buying $1000 In RSG: If an investor had bought $1000 of RSG stock 15 years ago, it would be worth $8,464.43 today based on a price of $186.81 for RSG at the time of writing.
<h3>Republic Servs's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715799633_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Republic Servs 15 Years Ago Would Be Worth Today

In the preceding three months, 4 analysts have released ratings for Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $9.5, a high estimate of $10.00, and a low estimate of $9.00. This current average has decreased by 6.13% from the previous average price target of $10.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1715799632_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Pediatrix Medical Group by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$10.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Pediatrix Medical Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pediatrix Medical Group compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Pediatrix Medical Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pediatrix Medical Group's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pediatrix Medical Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Pediatrix Medical Group Better</h2>
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment and generates majority of the revenue through neonatology and other pediatric subspecialties.
<h3>Financial Milestones: Pediatrix Medical Group's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Pediatrix Medical Group showcased positive performance, achieving a revenue growth rate of 0.83% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pediatrix Medical Group's net margin excels beyond industry benchmarks, reaching 0.81%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Pediatrix Medical Group's ROE excels beyond industry benchmarks, reaching 0.47%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Pediatrix Medical Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.18% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Pediatrix Medical Group's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.91, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 4 Analyst Ratings For Pediatrix Medical Group

Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>) has outperformed the market over the past 5 years by 11.64% on an annualized basis producing an average annual return of 24.68%. Currently, Eagle Materials has a market capitalization of $9.35 billion. 
Buying $1000 In EXP: If an investor had bought $1000 of EXP stock 5 years ago, it would be worth $3,045.98 today based on a price of $271.50 for EXP at the time of writing.
<h3>Eagle Materials's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715799628_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today

Oshkosh's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) short percent of float has fallen 25.79% since its last report. The company recently reported that it has 1.21 million shares sold short, which is 2.82% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Oshkosh Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715799622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Oshkosh has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Oshkosh's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Oshkosh's peer group average for short interest as a percentage of float is 4.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Oshkosh's Recent Short Interest

New York Community's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYCB#NYSE">NYCB</a>) short percent of float has risen 10.36% since its last report. The company recently reported that it has 78.92 million shares sold short, which is 11.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>New York Community Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715799617_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for New York Community has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing New York Community's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, New York Community's peer group average for short interest as a percentage of float is 4.89%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NYCB

(NYCB) - Analyzing New York Community's Short Interest

The New York Federal Reserve believes that several regional banks throughout the country are at risk of failure due to their overexposure to commercial loans. The Fed cited an analysis by the Klaros Group, which studied 4,000 American banks and found 282 could go under if their commercial loan portfolios were to fail. The good news for American consumers is that most of those banks are smaller and hold less than $10 billion in assets.
Although, it's never good news to hear that nearly 300 American banks are in danger of going out of business, the larger take-away is that the commercial loan crisis may not spell the kind of major risk to America's economy that existed in 2008. The current commercial loan crisis is being driven by several factors. However, the main culprit is historically high vacancy rates in America's office space.
By some estimates, America's current commercial/office property vacancy rate is almost 20% and some markets are even worse off than that. The high vacancy rates are proving to be a major issue for both the developers who own the buildings and the banks who lend them capital. In the past, they would simply have been able to refinance the debt, but that is proving to be much more difficult in today's banking climate.
Don't Miss:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">Here's how you can collect passive rental income without being a landlord</a>.</li>
<li>Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US. <a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital">Investing in its booming real estate market has never been more accessible</a>. </li>
</ul>
After the financial crisis, many of America's regional banks turned toward commercial lending because they viewed it as a safer option than residential mortgages. On the surface, that gamble made sense for several reasons. First, commercial borrowers tended to be more sophisticated and better resourced than residential homebuyers from a capital standpoint. Second, the long-term structure of office leases provided both banks and developers with what looked like a consistent source of revenue.
It was all going according to plan until COVID-19. The crisis pushed millions of Americans out of their office cubicles and turned them into remote workers. What no one could have foreseen at the time was that millions of those remote workers would never return to the office at all. That new reality had an incredibly damaging effect on the commercial office market by creating millions of square feet worth of vacant office space.
Commercial property developers suddenly found themselves facing double-digit vacancy rates on buildings that could only cover their debts and make profits with occupancy rates below 5%. It wasn't long before the regional banks, who made the loans, found themselves seated next to cash-strapped developers on the struggle bus. By this point, the Federal Reserve had begun <a href="https://www.benzinga.com/real-estate/24/05/38764935/suze-orman-says-todays-high-mortgage-rates-are-an-important-lesson">raising interest rates</a> and refinancing was no longer an option.
Trending:
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/real-estate/23/05/32554601/want-to-grow-your-wealth-passively-these-high-yield-real-estate-notes-might-be-your-holy-grail">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>
Pretty soon, it became clear that many regional lenders were overexposed to commercial real estate defaults and some of them began to go under. One of the most surprising bank failures was by California-based First Republic who languished on the verge of insolvency for weeks until it was purchased by JP Morgan Chase. Since then, nerves have been rattled, and the fact that almost one trillion dollars in commercial loans maturing in 2024 isn't helping.
The good news, if it can be called that, is that the Klaros study indicates that <a href="https://www.benzinga.com/insights/options/24/05/38821589/looking-at-bank-of-americas-recent-unusual-options-activity">America's largest banks</a> (like JP Morgan Chase) are at comparatively less risk than the regional lenders. It's also a good sign that the 282 banks on Klaros' watch list are not on the verge of collapse.
In an interview with CNBC, Klaros' co-founder Brian Graham said, "Most of these banks aren&#8217;t insolvent or even close to insolvent. They&#8217;re just stressed. That means there&#8217;ll be fewer bank failures. But it doesn&#8217;t mean that communities and customers don&#8217;t get hurt." Overall, it's a positive assessment, but Graham's sunny outlook must be tempered by the knowledge that the commercial loan crisis is at its beginning, and not anywhere near the end stage.
Read Next:
<ul>
<li>Passive income investments are one of the most trusted methods for riding out a recession, so it's no surprise that people are turning to this <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">Jeff Bezos-backed startup to generate monthly rental income without having to purchase their own property</a>.</li>
<li>Commercial real estate has historically outperformed the stock market, but few investors have the capital or resources needed to invest in this asset class. This platform <a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate">allows individuals to invest in commercial real estate with as little as $5,000. </a></li>
</ul>

Real Estate

New York Federal Reserve Predicts More Bank Failures

AECOM's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) short percent of float has fallen 24.82% since its last report. The company recently reported that it has 1.06 million shares sold short, which is 1.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.95 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AECOM Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715799612_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AECOM has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AECOM's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AECOM's peer group average for short interest as a percentage of float is 4.73%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(ACM) - Analyzing AECOM's Short Interest

Over the past 24 hours, Ethereum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) price has risen 3.89% to $2,998.19. This is contrary to its negative trend over the past week where it has experienced a 1.0% loss, moving from $3,008.48 to its current price. As it stands right now, the coin's all-time high is $4,878.26. 
The chart below compares the price movement and volatility for Ethereum over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715799604_0.png" alt="price_chart" />
The trading volume for the coin has climbed 5.0% over the past week, moving opposite, directionally, with the overall circulating supply of the coin, which has decreased 0.1%. This brings the circulating supply to 120.12 million. According to our data, the current market cap ranking for ETH is #2 at $359.04 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715799604_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$ETH

Ethereum's Price Increased More Than 3% Within 24 hours

INVO, EZGO and WISA among pre-market losers

Veru, EyePoint Pharmaceuticals, SINTX Technologies among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Friday is here and we&rsquo;re breaking down the biggest pre-market stock movers that traders need to know about this morning!



Moving stocks this morning are shareholder meetings, earnings reports, a dividend and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Redwoods Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/rwodu-stock-quote/">RWODU</a>) stock is rocketing more than 84% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318243471&amp;type=PDF&amp;symbol=RWOD&amp;cdn=b571d8a48f5cf4a43db1e1aee09248ab&amp;companyName=Redwoods+Acquisition+Corp.&amp;formType=425&amp;formDescription=Prospectuses+and+communications%2C+business+combinations&amp;dateFiled=2024-04-18">details of a shareholder meeting</a>.</li>



<li>Zhongchao (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcmd-stock-quote/">ZCMD</a>) shares are soaring over 83% with heavy pre-market trading.</li>



<li>Redwoods Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/rwod-stock-quote/">RWOD</a>) stock is also surging more than 69% on that shareholder meeting.</li>



<li>Wang &amp; Lee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wlgs-stock-quote/">WLGS</a>) shares are gaining over 33% with its <a href="https://www.nasdaq.com/press-release/wang-lee-group-inc.-announces-fiscal-year-2023-financial-results-2024-04-18">2023 earnings report</a>.</li>



<li>Next e GO (NASDAQ:<a href="https://investorplace.com/stock-quotes/egox-stock-quote/">EGOX</a>) stock is increasing more than 23% on strong early morning trading.</li>



<li>Ault Alliance (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ault-stock-quote/">AULT</a>) shares are rising over 23% after <a href="https://finance.yahoo.com/news/ault-alliance-declares-monthly-cash-103000927.html">announcing a cash dividend</a>.</li>



<li>Hub Cyber Security (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/">HUBC</a>) stock is climbing more than 23% with heavy trading this morning.</li>



<li>Trio Petroleum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tpet-stock-quote/">TPET</a>) shares are jumping close to 22% as it <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318243734&amp;type=PDF&amp;symbol=TPET&amp;cdn=802b738c707aac03352a0b144f6bbbb7&amp;companyName=Trio+Petroleum+Corp.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-19">plans for an annual shareholder meeting</a>.</li>



<li>Richtech Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rr-stock-quote/">RR</a>) stock is getting an over 20% boost despite a lack of news this morning.</li>



<li>Centogene (NASDAQ:<a href="https://investorplace.com/stock-quotes/cntg-stock-quote/">CNTG</a>) shares are up more than 19% without any apparent news today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Tritium DCFC (NASDAQ:<a href="https://investorplace.com/stock-quotes/dcfc-stock-quote/">DCFC</a>) stock is crashing over 61% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318241881&amp;type=PDF&amp;symbol=DCFC&amp;cdn=21bc4c0fb2af1dc1e7b76f221263a80e&amp;companyName=Tritium+DCFC+Limited&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-04-18">warning of insolvency</a>.</li>



<li>BioNexus Gene Lab (NASDAQ:<a href="https://investorplace.com/stock-quotes/bglc-stock-quote/">BGLC</a>) shares are plummeting more than 23% following a <a href="https://www.nasdaq.com/press-release/bionexus-gene-lab-corp.-agrees-to-invest-rm-1.2-million-in-ascension-innovation-aisb">rally late yesterday</a>.</li>



<li>Tian Ruixiang (NASDAQ:<a href="https://investorplace.com/stock-quotes/tirx-stock-quote/">TIRX</a>) stock is diving over 18% after a <a href="https://investorplace.com/2024/04/why-is-tian-ruixiang-tirx-stock-up-209-today/">massive rally yesterday</a>.</li>



<li>iSpecimen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ispc-stock-quote/">ISPC</a>) shares are tumbling more than 17% after a major rally on Thursday.</li>



<li>Spectaire (NASDAQ:<a href="https://investorplace.com/stock-quotes/spec-stock-quote/">SPEC</a>) stock is taking an over 17% beating on Friday morning.</li>



<li>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) shares are falling more than 16% this morning.</li>



<li>Moolec Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlec-stock-quote/">MLEC</a>) stock is dropping nearly 16% with its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318243156&amp;type=PDF&amp;symbol=MLEC&amp;cdn=8dae77192b72d42d8942b9dec934f931&amp;companyName=Moolec+Science+SA&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-04-18">latest earnings release</a>.</li>



<li>AGBA Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/agba-stock-quote/">AGBA</a>) shares are retreating over 15% after <a href="https://investorplace.com/2024/04/why-is-agba-group-agba-stock-up-149-today/">soaring yesterday on merger plans</a>.</li>



<li>MariaDB (NYSE:<a href="https://investorplace.com/stock-quotes/mrdb-stock-quote/">MRDB</a>) stock is decreasing more than 13% this morning.</li>



<li>Invo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) shares close out our pre-market stock movers down over 13% after <a href="https://investorplace.com/2024/04/why-is-invo-bioscience-invo-stock-up-85-today/">a recent rally</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-19th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

LI, VERU and MRIN among pre-market losers

Predictive Oncology, BIMI Holdings, IMAC Holdings among healthcare movers

INVO Bioscience (INVO) just unveiled an announcement. INVO Bioscience, through its subsidiary INVO Centers, has assigned its Tampa property lease t...

INVO Bioscience Navigates Lease Assignment and Nasdaq Woes

SBFM, BPTH and INDO among pre-market losers

Bio-Path Holdings, Sunshine Biopharma, INVO Bioscience among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Tuesday morning!



<a href="https://investorplace.com/stock-types/meme-stocks/">Meme stocks</a> continue to rally, companies release earnings reports, and more market news has shares moving today.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>AMC Entertainment (NYSE:<a href="https://investorplace.com/stock-quotes/amc-stock-quote/">AMC</a>) stock is rocketing more than 59% as <a href="https://twitter.com/TheRoaringKitty">Roaring Kitty&rsquo;s return</a> continues to bolster the shares.</li>



<li>GameStop (NYSE:<a href="https://investorplace.com/stock-quotes/gme-stock-quote/">GME</a>) shares are soaring over 54% alongside the return of Roaring Kitty.</li>



<li>MicroCloud Hologram (NASDAQ:<a href="https://investorplace.com/stock-quotes/holo-stock-quote/">HOLO</a>) stock is surging 41% with heavy pre-market trading.</li>



<li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) shares are gaining more than 34% with strong early morning trading today.</li>



<li>Warrantee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock is increasing over 27% without any clear news this morning.</li>



<li>BlackBerry (NYSE:<a href="https://investorplace.com/stock-quotes/bb-stock-quote/">BB</a>) shares are rising more than 24% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318312931&amp;type=PDF&amp;symbol=BB&amp;cdn=4b26c072318efaefdc3ba22b7b5e8deb&amp;companyName=BlackBerry+Limited&amp;formType=DEFA14A&amp;formDescription=Additional+proxy+soliciting+materials+-+definitive&amp;dateFiled=2024-05-13">shareholder meeting update</a>.</li>



<li>Rent the Runway (NASDAQ:<a href="https://investorplace.com/stock-quotes/rent-stock-quote/">RENT</a>) stock is climbing over 19% this morning.</li>



<li>SunPower (NASDAQ:<a href="https://investorplace.com/stock-quotes/spwr-stock-quote/">SPWR</a>) shares are heading more than 19% higher <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318314743&amp;type=PDF&amp;symbol=SPWR&amp;cdn=ecf4fe81973e2491082785bf9c740edb&amp;companyName=SunPower+Corporation&amp;formType=NT+10-Q&amp;formDescription=Notification+of+inability+to+timely+file+Form+10-Q+or+10-QSB&amp;dateFiled=2024-05-13">despite a delayed filing</a>.</li>



<li>AMTD Digital (NYSE:<a href="https://investorplace.com/stock-quotes/hkd-stock-quote/">HKD</a>) stock is jumping over 18% on Tuesday morning.</li>



<li>Koss (NASDAQ:<a href="https://investorplace.com/stock-quotes/koss-stock-quote/">KOSS</a>) shares are up more than 16% <a href="https://investorplace.com/2024/05/blast-from-the-past-former-meme-koss-stock-soars-on-roaring-kitty-news/">alongside the meme stock rally</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Inotiv (NASDAQ:<a href="https://investorplace.com/stock-quotes/notv-stock-quote/">NOTV</a>) stock is plummeting over 34% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318314218&amp;type=PDF&amp;symbol=NOTV&amp;cdn=ebe87b345e7637122dc6a4d631ded890&amp;companyName=Inotiv+Inc.&amp;formType=NT+10-Q&amp;formDescription=Notification+of+inability+to+timely+file+Form+10-Q+or+10-QSB&amp;dateFiled=2024-05-13">alongside preliminary earnings</a>.</li>



<li>Augmedix (NASDAQ:<a href="https://investorplace.com/stock-quotes/augx-stock-quote/">AUGX</a>) shares are diving close to 33% after releasing its <a href="https://www.nasdaq.com/press-release/augmedix-delivers-40-revenue-growth-for-first-quarter-of-2024-2024-05-13">latest earnings report</a>.</li>



<li>Scorpius (NYSEMKT:<a href="https://investorplace.com/stock-quotes/scpx-stock-quote/">SCPX</a>) stock is tumbling more than 22% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318315844&amp;type=PDF&amp;symbol=SCPX&amp;cdn=2f4148150720f83231bf9f50680f426c&amp;companyName=Scorpius+Holdings+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-05-13">with a public offering</a>.</li>



<li>Akoya Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/akya-stock-quote/">AKYA</a>) shares are taking an over 19% beating after <a href="https://www.marketwatch.com/story/shares-of-akoya-biosciences-drop-after-1q-earnings-revenue-outlook-miss-c9dded98?mod=newsviewer_click">missing Q1 estimates</a>.</li>



<li>Eastside Distilling (NASDAQ:<a href="https://investorplace.com/stock-quotes/east-stock-quote/">EAST</a>) stock is dropping more than 18% after <a href="https://www.nasdaq.com/press-release/eastside-distilling-reports-first-quarter-2024-financial-results-2024-05-13">posting its Q1 results</a>.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are sliding over 14% this morning.</li>



<li>Terran Orbital (NYSE:<a href="https://investorplace.com/stock-quotes/llap-stock-quote/">LLAP</a>) stock is falling more than 14% with its <a href="https://www.businesswire.com/news/home/20240514904938/en/Terran-Orbital-Reports-First-Quarter-2024-Financial-Results">Q1 earnings report</a>.</li>



<li>Hanryu (NASDAQ:<a href="https://investorplace.com/stock-quotes/hryu-stock-quote/">HRYU</a>) shares are slipping over 13% this morning.</li>



<li>Invo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is dipping more than 12% today.</li>



<li>Intelligent Living (NASDAQ:<a href="https://investorplace.com/stock-quotes/ilag-stock-quote/">ILAG</a>) shares close out our pre-market stock movers down over 12% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-may-14th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

INVO Bioscience Stock (NASDAQ:INVO), Short Interest Report

People Also Watch